Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
Last updated on April 2022Recruitment
- Recruitment Status
- Terminated
- Estimated Enrollment
- 12
Inclusion Criteria
- Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy.
- Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active cancer or post treatment are allowed on the study.
- Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy.
- Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active cancer or post treatment are allowed on the study.
Summary
- Conditions
- Cancer
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy.
- Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active cancer or post treatment are allowed on the study.
- Patients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy.
- Patients with histologically confirmed diagnosis of cancer NOTE: Patients with active cancer or post treatment are allowed on the study.
Tracking Information
- NCT #
- NCT02078089
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Costantine Albany, M.D. Indiana University
- Costantine Albany, M.D. Indiana University
Get Well Soon